Zucara Therapeutics is developing ZT-01, a first-in-class, once-daily therapeutic to prevent hypoglycemia in people with T1D and insulin-dependent Type 2 diabetes. ZT-01 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with these conditions. ZT-01 is designed to restore glucagon secretion to prevent hypoglycemia, which could dramatically change diabetes disease management and improve both patient health and quality of life. For more information, visit www.zucara.ca.
Company Details
- Employees
- 11
- Founded
- -
- Address
- 661 University Ave, 1300,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- zucara.ca
- Keywords
- diabetes, hypoglycemia, drug therapy, insulin.
- HQ
- Toronto, Ontario
Zucara Therapeutics Inc. Questions
Zucara Therapeutics Inc.'s website is zucara.ca
Zucara Therapeutics Inc.'s LinkedIn profile is https://ca.linkedin.com/company/zucara-therapeutics-inc-
Zucara Therapeutics Inc. has
11 employees.
View email and phone details for 11
employees at Zucara Therapeutics Inc..
Zucara Therapeutics Inc.'s industry is
Biotechnology Research
Zucara Therapeutics Inc.'s top competitors are
Admare Bioinnovations,
Eupraxia Pharmaceuticals Inc.,
Perceptive Advisors,
Xenon Pharmaceuticals Inc.,
Life Sciences Ontario,
Voxcell Bioinnovation,
Trudell Medical Limited,
Tiap - Toronto Innovation Acceleration Partners,
Nervgen Pharma Corp.,
Xontogeny.
Zucara Therapeutics Inc.'s categories are Biotechnology Research
Zucara Therapeutics Inc.'s founding year is 2015
